Lowering Uric Acid in Live Kidney Donors

Exclusion Criteria

• •1. Adverse reactions to allopurinol or other xanthine oxidase inhibitors
• •2. Use of uric acid lowering therapy within 3 months
• •3. History of gout, xanthinuria or other indications for uric acid lowering therapy such as cancer chemotherapy
• •4. History of renal calculi
• •5. History of coronary heart disease
• •6. Heart failure with left ventricular ejection fraction \<45%
• •7. History of significant (i.e. non-physiological) cardiac valvular stenosis or insufficiency
• •8. History of clinically significant hepatic disease including hepatitis B or C and/or ALAT (SGPT) above the upper reference limit at screening.
• •9. History of HIV or AIDS
• •10. Severe systemic infections, current or within the last 6 months
• •11. History of malignancy other than localized basal cell carcinoma of the skin, treated or untreated, within the past 5 years.
• •12. Other life-threatening diseases
• •13. Haemoglobin concentration \< 11 g/dL(males), \<10 g/dL (females); white blood cell (WBC) count \< 3.5 \* 10\^9/L; platelet count \<50 \*10\^9/L at screening
• •14. Use of the following medications at or within 14 days before the screening visit: azathioprine, mercaptopurine, vidarabin, chlorpropamide, warfarin, tamoxifen, theophylline, amoxicillin/ampicillin, cyclophosphamide, doksorubicin, bleomycin, prokarbazin, cyclosporine, didanosine.
• •15. Contraindications to MRI, including: Magnetic intracranial clips. Metal fragments in orbita. Cochlea (ear) implant. Neurostimulator. Pacemaker/ICD or remaining pacemaker electrodes. Harrington rods in thorax. Claustrophobia. Unable to lie supine.
• •16. Pregnant or nursing (lactating) women
• •17. Fertile women, unless they are using effective contraception during dosing of study treatment
• •18. Any reason why, in the opinion of the investigator, the patient should not participate.